This Is Ascent Health Services – the Secretive Swiss Company at the Heart of the Express Scripts Scandal

Key Takeaways

• Ascent is a Swiss‑registered GPO owned by Cigna.
• Collects manufacturer fees instead of passing rebates to clients.
• Generated $7.6 billion in GPO fees in 2022 alone.
• FTC settlement forces Ascent to relocate to the United States.
• Court cases allege fraud and opaque pricing across major PBMs.

Pulse Analysis

The rise of group‑purchasing organizations (GPOs) within pharmacy‑benefit managers (PBMs) reflects a strategic shift toward offshore financial engineering. Ascent, founded by Cigna’s Express Scripts, leverages Switzerland’s low corporate tax regime and transfer‑pricing rules to reclassify manufacturer rebates as administrative fees. This maneuver not only shields billions in revenue from U.S. tax authorities but also obscures the true cost of prescription drugs from plan sponsors, undermining the original GPO promise of downstream savings.

Regulators have begun to crack down. The Federal Trade Commission’s 2026 settlement mandates that Ascent abandon its Swiss domicile, decouple fees from drug list prices, and submit to a decade of monitoring. Simultaneously, federal and state courts have entertained racketeering and deceptive‑trade‑practice suits alleging that Ascent and its peers, Zinc and Emisar, retain rebates that should flow to employers and unions. An Office of Personnel Management audit revealed a $45 million overcharge to the postal workers’ health plan, with nearly $16 million attributed directly to Ascent’s fee structure. These actions signal a broader willingness to pierce the opacity that has long protected PBM profit margins.

The fallout could reshape the pharmaceutical supply chain. If Ascent is reshored and fee transparency enforced, PBMs may lose a lucrative revenue stream, prompting them to renegotiate contracts or seek alternative profit mechanisms. Lawmakers are also eyeing reforms to extend rebate‑passthrough rules to GPO fees, potentially curbing the incentive to offshore such arrangements. For employers, unions and policymakers, the scrutiny of Ascent offers a rare glimpse into the hidden economics of drug pricing and a possible pathway toward lower out‑of‑pocket costs for American patients.